The stock of Revelation Biosciences Inc (NASDAQ: REVB) has decreased by -8.09 when compared to last closing price of 0.34.Despite this, the company has seen a loss of -23.75% in its stock price over the last five trading days. businesswire.com reported 2024-12-03 that SAN DIEGO–(BUSINESS WIRE)—- $REVB #REVB–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 (the “Existing Warrants”), at the exercise.
Is It Worth Investing in Revelation Biosciences Inc (NASDAQ: REVB) Right Now?
Moreover, the 36-month beta value for REVB is 0.31. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REVB is 8.35M and currently, short sellers hold a 1.51% of that float. On December 20, 2024, REVB’s average trading volume was 1.01M shares.
REVB’s Market Performance
The stock of Revelation Biosciences Inc (REVB) has seen a -23.75% decrease in the past week, with a -59.56% drop in the past month, and a -62.74% fall in the past quarter. The volatility ratio for the week is 13.33%, and the volatility levels for the past 30 days are at 13.07% for REVB. The simple moving average for the past 20 days is -41.55% for REVB’s stock, with a -79.05% simple moving average for the past 200 days.
REVB Trading at -56.60% from the 50-Day Moving Average
After a stumble in the market that brought REVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.75% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 13.33%, as shares sank -58.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.89% lower at present.
During the last 5 trading sessions, REVB fell by -23.75%, which changed the moving average for the period of 200-days by -89.51% in comparison to the 20-day moving average, which settled at $0.5382. In addition, Revelation Biosciences Inc saw -97.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for REVB
Current profitability levels for the company are sitting at:
- -227.47 for the present operating margin
- 0.47 for the gross margin
The net margin for Revelation Biosciences Inc stands at -412.94. The total capital return value is set at -3.2. Equity return is now at value -270.02, with -148.06 for asset returns.
Currently, EBITDA for the company is 95208.0 with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of -104.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To wrap up, the performance of Revelation Biosciences Inc (REVB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
